Evolus (EOLS) Trading Up 6.4%
Shares of Evolus Inc (NASDAQ:EOLS) were up 6.4% during trading on Tuesday . The stock traded as high as $26.50 and last traded at $25.94. Approximately 527,264 shares changed hands during trading, a decline of 52% from the average daily volume of 1,087,760 shares. The stock had previously closed at $24.38.
Several analysts recently commented on EOLS shares. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Evolus in a research report on Thursday, April 4th. SunTrust Banks assumed coverage on Evolus in a report on Wednesday, March 20th. They issued a “buy” rating and a $30.00 target price for the company. Mizuho upped their target price on Evolus from $25.00 to $29.00 and gave the company a “buy” rating in a report on Tuesday, March 19th. Stifel Nicolaus assumed coverage on Evolus in a report on Monday, January 28th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Zacks Investment Research upgraded Evolus from a “sell” rating to a “hold” rating in a report on Monday, January 14th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Evolus currently has an average rating of “Buy” and a consensus price target of $30.71.
The firm has a market cap of $664.96 million, a PE ratio of -16.52 and a beta of 5.37.
Large investors have recently modified their holdings of the business. Meeder Asset Management Inc. grew its holdings in Evolus by 48.9% in the 1st quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock valued at $39,000 after buying an additional 569 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of Evolus by 239.6% during the 4th quarter. IFP Advisors Inc now owns 8,490 shares of the company’s stock worth $101,000 after purchasing an additional 5,990 shares during the period. Valeo Financial Advisors LLC purchased a new position in shares of Evolus during the 1st quarter worth $108,000. Wells Fargo & Company MN grew its holdings in shares of Evolus by 860.3% during the 3rd quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after purchasing an additional 5,325 shares during the period. Finally, Rhumbline Advisers purchased a new position in shares of Evolus during the 4th quarter worth $129,000. Institutional investors own 19.82% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/evolus-eols-trading-up-6-4/2983134.html.
Evolus Company Profile (NASDAQ:EOLS)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Story: How does a reverse stock split work?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.